References

1. Bennett JM, Komrokji R, Kouides P: The myelodysplastic syndromes. In: Abeloff Martin D, Armitage James O, Niederhuber John E., et al. (eds.) Clinical Oncology. 3rd ed. New York: Churchill Livingstone; 2004.

2. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of theacute leukaemias. French-American-British (FAB) Co-operative Group. Br J Haematol 33:451-458, 1976.

3. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.

4. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835-3849, 1999.

5. Aul C, Gattermann N, Schneider W: Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358-367, 1992.

6. Pomeroy C, Oken MM, Rydell RE, et al: Infection in the myelodysplastic syndromes. Am J Med 90:338-344, 1991.

7. Gallagher A, Darley RL, Padua R: The molecular basis of myelodysplastic syndromes. Haematologica 82:191-204, 1997.

8. Smith MA, Smith JG: The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 15:597-601, 1991.

9. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al.: Haematological response of patients with myelodysplas-tic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102:1314-1322, 1998.

10. Kitagawa M, Saito I, Kuwata T, et al.: Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049-2054, 1997.

11. Deeg HJ, Beckham C, Loken MR, et al.: Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 37: 405-414, 2000.

12. Yoshida Y: The role of apoptosis in the myelodysplastic syndromes. In: Bennett JM (ed.) The Myelodysplastic Syndromes:Pathobiology and Clinical Management. New York: Marcel Dekker;2002:177-201.

13. Prchal JT, Throckmorton DW, Carroll AJ, et al.: A common progenitor for human myeloid and lymphoid cells. Nature 274:590-591, 1978.

14. Amenomori T, Tomonaga M, Jinnai I, et al.: Cytogenetic and cytochemical studies on progenitor cells of primary acquired sideroblastic anemia (PASA): involvement of multipotent myeloid stem cells in PASA clone and mosaicism with normal clone. Blood 70:1367-1372, 1987.

15. Anastasi J, Feng J, Le Beau MM, et al.: Cytogenetic clon-ality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 81:1580-1585, 1993.

16. Lawrence HJ, Broudy VC, Magenis RE, et al.: Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias. Blood 70:1003-1005, 1987.

17. Janssen JW, Buschle M, Layton M, et al.: Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73:248-254, 1989.

18. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci US. 68:820-823, 1971.

19. Song WJ, Sullivan MG, Legare RD, et al.: Haploinsufficiency of CBFA2 causes familial thrombocy-topenia with propensity to develop acute myelogenous leukaemia. Nature Genetics 23:166-175, 1999.

20. Fenaux P, Morel P, Lai JL: Cytogenetics of myelodysplas-tic syndromes. Semin Hematol 33:127-138, 1996.

21. Nakamura K, Inokuchi K, Dan K: Abnormalities of the p53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes. J Nippon Med Sch 68:143-148, 2001.

22. Quesnel B, Guillerm G, Vereecque R, et al.: Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990, 1998.

23. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17:1813-1819, 2003.

24. Sheikhha MH, Tobal K, Liu Yin JA: High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 117:359-365, 2002.

25. Larson RA, Wang Y, Banerjee M, et al.: Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94:803-807, 1999.

26. Naoe T, Takeyama K, Yokozawa T, et al.: Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6:4091-4095, 2000.

27. Hofmann WK, de Vos S, Komor M, et al.: Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553-3560, 2002.

28. Miyazato A, Ueno S, Ohmine K, et al.: Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98:422-427, 2001.

29. Ueda M, Ota J, Yamashita Y, et al.: DNA micro array analysis of stage progression mechanism in myelodys-plastic syndrome. Br J Haematol 123:288-296, 2003.

30. Vallespi T, Imbert M, Mecucci C, et al.: Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83:258-275, 1998.

31. Olney HJ, Le Beau MM: The cytogenetics of myelodys-plastic syndromes. Best Pract Res Clin Haematol 14:479-495, 2001.

32. Brunning RD BJ, Flandrin G, et al.: Myelodysplastic syndromes. In: Jaffe E Harris N, Stein H (eds.) Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001:61.

33. West RR, Stafford DA, White AD, et al.: Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 95: 2093-2097, 2000.

34. Mecucci C: Molecular features of primary MDS with cytogenetic changes. Leuk Res 22:293-302, 1998.

35. Loss of the Y chromosome from normal and neoplastic bone marrows. United Kingdom Cancer Cytogenetics Group (UKCCG). Genes Chromosomes Cancer 5:83-88, 1992.

36. Li T, Xue Y, Wu Y, et al.: Clinical and molecular cytoge-netic studies in seven patients with myeloid diseases characterized by i(20q-). Br J Haematol 125:337-342, 2004.

37. Pedersen-Bjergaard J, Philip P: Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 55:119-124, 1991.

38. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al.: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542-3552, 1995.

39. Carroll M, Tomasson MH, Barker GF, et al.: The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 93:14845-14850, 1996.

40. Sternberg DW, Tomasson MH, Carroll M, et al.: The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood 98:3390-3397, 2001.

41. Cain JA, Grisolano JL, Laird AD, et al.: Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 2004. [Epub ahead of print.]

42. Magnusson MK, Meade KE, Nakamura R, et al.: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion onco-gene. Blood 100:1088-1091, 2002.

43. Magnusson MK, Meade KE, Brown KE, et al.: Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98:2518-2525, 2001.

44. Ross TS, Bernard OA, Berger R, et al.: Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91:4419-4426, 1998.

45. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogene 55:57-65, 1991.

46. Keung YK, Beaty M, Powell BL, et al.: Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 28:579-586, 2004.

47. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodys-plastic syndromes. Blood 89:2079-2088, 1997.

48. Komrokji R, Bennett JM. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep 2:179-185, 2003.

49. Yoshida Y: Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 7:144-146, 1993.

50. Rajapaksa R, Ginzton N, Rott LS, et al.: Altered oncopro-tein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275-4287,1996.

51. Parker JE, Fishlock KL, Mijovic A, et al.: "Low-risk" myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 103:1075-1082, 1998.

52. Bogdanovic AD, Trpinac DP, Jankovic GM, et al.: Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 11:656-659, 1997.

53. Raza A, Mundle S, Shetty V, et al.: Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 63:265-278,1996.

54. Allampallam K, Shetty VT, Raza A: Cytokines and MDS. Cancer Treat Res 108:93-100, 2001.

55. Bouscary D, De Vos J, Guesnu M, et al.: Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11:839-845, 1997.

56. Deeg HJ: Marrow stroma in MDS: culprit or bystander? Leuk Res 26:687-688, 2002.

57. Flores-Figueroa E, Gutierrez-Espindola G, Guerrero-Rivera S, et al.: Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk Res 23:385-394,1999.

58. Coutinho LH, Geary CG, Chang J, et al.: Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 75:16-25, 1990.

59. Aizawa S, Nakano M, Iwase O, et al.: Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23:239-246, 1999.

60. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, et al.: In vitro characterization of hematopoietic microenvironment cells from patients with myelodys-plastic syndrome. Leuk Res 26:677-686, 2002.

61. Rami Komrokji, Jainulabdeen J Ifthikharuddin, Raymond E Felgar, et al.: Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: casreport and literature review. Am J Hematol 76, 2004 (in press)

62. Bennett JM: World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133, 2000.

63. Tham KT CJ, Macon WR: Silver stain for ringed siderob-lasts. A sensitive method that differs from Perls' reaction in mechanism and clinical application. Am J Clin Pathol 94:73, 1990.

64. Ho PJ GJ, Vincent P, Joshua D: The myelodysplastic syndromes: diagnostic criteria and laboratory evaluation (review). Pathology 25:297, 1993.

65. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 66:117, 1993.

66. Tricot G, De Wolf-Peeters C, HendrickxB, et al.: Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 57:423-430,1984.

67. Rios A, Canizo MC, Sanz MA, et al.: Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 75:26-33, 1990.

68. Tricot G, De Wolf-Peeters C, Vlietinck R, et al.: Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 58:217-225, 1984.

69. Seo IS, Li CY, Yam LT: Myelodysplastic syndrome: diagnostic implications of cytochemical and immunocyto-chemical studies. Mayo Clin Proc 68:47-53,1993.

70. Scott CS, Cahill A, Bynoe AG, et al.: Esterase cytochemistry in primary myelodysplastic syndromes and mega-loblastic anaemias: demonstration of abnormal staining patterns associated with dysmyelopoiesis. Br J Haematol 55:411-418,1983.

71. Kawaguchi M, Nehashi Y, Aizawa S, et al.: Comparative study of immunocytochemical staining versus Giemsa stain for detecting dysmegakary-opoiesis in myelodysplastic syndromes (MDS). Eur J Haematol 44:89-94,1990.

72. Stetler-Stevenson M, Arthur DC, Jabbour N, et al.: Diagnostic utility of flow cytometric immunophenotyp-ing in myelodysplastic syndrome. Blood 98:979-987, 2001.

This page intentionally left blank

Chapter 39

0 0

Post a comment